Form 4: AN2 Therapeutics Director's Stock Options Repriced

AN2 Therapeutics' Director Gilbert Lynn Marks had 44,769 stock options repriced to $3.91 per share, contingent on future events.

Summary

• Director Gilbert Lynn Marks' stock options were repriced on March 19, 2026.
• A total of 44,769 stock options were affected by the repricing.
• The new exercise price for these options is $3.91 per share, which was the closing price of AN2 Therapeutics' common stock on the repricing date.
• The original exercise prices for the disposed options were $6.596, $17.28, and $5.91.
• The repriced options are fully vested.
• The repricing was approved by the Issuer's board of directors on March 19, 2026.
• The exercise price will revert to the original higher price if the option is exercised or the reporting person's services terminate prior to the 'Premium End Date'.
• The 'Premium End Date' is the earliest of September 19, 2027, a change in control, or the reporting person's death or disability.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative signal for past stock performance, as option repricing typically occurs when the stock price has significantly declined, making existing options worthless. While it re-incentivizes the director, it reflects poorly on prior shareholder value creation.

Positives

• The exercise price for 44,769 stock options held by Director Gilbert Lynn Marks was significantly reduced to $3.91 per share, from previous prices of $6.596, $17.28, and $5.91, making them more 'in-the-money' or reducing their 'out-of-the-money' status.
• All repriced options are fully vested, meaning the director can exercise them immediately, subject to the repricing conditions.
• The repricing provides a renewed incentive for the director, aligning their interests with potential future stock price appreciation from the current lower base.

Negatives

• The repricing of options typically indicates a significant decline in the company's stock price from the original grant dates, suggesting poor past performance or market sentiment.
• Shareholders who purchased stock at higher prices may view option repricing negatively as it dilutes their equity value and rewards management despite underperformance.
• The contingent nature of the repricing, where the price reverts to the original higher value under certain conditions (e.g., exercise before Premium End Date), adds complexity and potential uncertainty for the reporting person.

Industry Context

StockSavvy.ai notes that option repricing is a common practice in industries, particularly biotechnology or high-growth sectors, where stock prices can be volatile. It is often used to re-incentivize executives and directors when the stock price has fallen significantly below previous grant prices, making existing options 'underwater' and less effective as a retention or performance tool. However, it can also be viewed critically by shareholders as a reward for underperformance.

Comparison to Industry Standards

• StockSavvy.ai observes that option repricing, while not uncommon, often draws scrutiny. For instance, companies like Zynga (2012) and Groupon (2012) faced shareholder backlash for repricing options after significant stock declines.
• In contrast, some companies, particularly in biotech, use repricing as a retention strategy during challenging periods, similar to how some smaller biotechs might adjust compensation structures to retain key talent during clinical trial setbacks or market downturns.
• The specific conditions for the repricing, such as the 'Premium End Date' and the reversion to original prices, are a less common but notable feature designed to mitigate some of the negative optics of a straightforward repricing.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact due to perceived dilution and rewarding management despite stock underperformance. May question governance practices related to executive compensation.
• Director (Gilbert Lynn Marks): Positive impact as previously 'underwater' options are now repriced to a lower, more favorable exercise price, increasing potential future gains and re-establishing incentive.
• Employees: Could potentially signal a broader compensation strategy to retain talent during challenging stock periods, which might be viewed positively by other employees with underwater options, or negatively if it's seen as preferential treatment for directors.

Key Dates

Recommendation

The option repricing for a director suggests past stock underperformance, which is a negative signal. However, the repricing also serves to re-incentivize key personnel, which could be a positive for future performance and retention. Given the mixed signals and the specific nature of a Form 4 filing, a 'hold' recommendation is appropriate as investors should await further financial or operational updates to assess the company's trajectory post-repricing.

Keywords

AN2 Therapeutics, ANTX, Form 4, Stock Options, Option Repricing, Insider Transaction, Director Compensation, Equity Compensation, Gilbert Lynn Marks, SEC Filing